Preparing for a New Era in Alzheimer's Disease: Debating New Targeted Biomarkers and Therapeutic Approaches : Episode 7
CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.
EP: 1.Apolipoprotein E4 in Alzheimer’s Disease
EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease
EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease
EP: 5.Contribution of Multiple Pathways to the Development of Alzheimer’s Disease
EP: 6.Utilization of Neuroimaging in Alzheimer’s Disease
Now Viewing
EP: 7.CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
EP: 8.Utilization of APOE4 Genotype in Management of Alzheimer’s Disease
EP: 9.Alzheimer’s Disease Pipeline
EP: 10.The Future Outlook for Alzheimer’s Disease
Video content above is prompted by the following questions:
- Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
- What are the unmet needs?
Related Videos
Related Content
